The medical technology industry stands at a critical juncture. As healthcare systems globally demand procedures that reduce patient trauma, shorten recovery times, and lower hospital readmission rates, the pressure on medical device manufacturers (OEMs) and visionary startups has never been higher. Minimally invasive surgery (MIS) is no longer a sub-specialty or a luxury; it is the definitive gold standard across cardiology, orthopedics, neurology, and general surgery.
Against this backdrop of rapid evolution, Medical Design & Outsourcing (MDO) has announced the return of its flagship MDO Min-Vasive Medtech Webinar Series, scheduled to run from August 18–20, 2026. This year’s event carries immense anticipation, driven by the announcement that the series will kick off with one of the most prolific, disruptive, and successful figures in the history of cardiovascular implants: Manny Villafaña.
As a living legend in the medtech landscape, Villafaña’s career is a masterclass in translating bold, counter-intuitive medical concepts into commercial realities that have saved millions of lives while generating tens of billions of dollars in enterprise value. His keynote session will open the three-day virtual event, setting a tone of uncompromising innovation, rigorous R&D strategy, and uncompromising regulatory navigation.
Registration for the 2026 MDO Min-Vasive Medtech webinar series is entirely free and grants attendees access to all three daily sessions, which run from 9:00 a.m. to 10:00 a.m. Pacific Time (11:00 a.m. Central / 1:00 p.m. Eastern). In addition to Villafaña, MDO is set to unveil two more industry-leading speakers in the coming weeks, rounding out a multi-day curriculum focused on the advanced materials, intricate components, and cutting-edge manufacturing processes that make next-generation minimally invasive procedures possible.
Detailed Chronology: Manny Villafaña and the Evolution of Modern Cardiovascular Care
To understand the weight of Manny Villafaña’s participation in the 2026 webinar series, one must examine a career that spans over half a century of pioneering medical device engineering. Villafaña is not merely an entrepreneur; he is a structural architect of the modern cardiovascular device industry. His entrepreneurial footprint is marked by a series of high-stakes ventures, groundbreaking technologies, and multi-billion-dollar corporate acquisitions.
The Foundation of Giants: CPI and St. Jude Medical
In the early 1970s, the field of cardiac pacing was in its relative infancy, dominated by rigid paradigms and limited technological reliability. Undeterred by the immense regulatory and technical hurdles of the era, Villafaña co-founded Cardiac Pacemakers Inc. (CPI). Under his guidance, CPI developed revolutionary pacing technologies that improved patient longevity and operational reliability. The company’s exceptional market performance and technological moat caught the eye of healthcare conglomerate Boston Scientific, which ultimately acquired CPI in a landmark transaction valued at $27 billion.
Rather than resting on his laurels, Villafaña turned his attention to another lethal cardiac pathology: diseased heart valves. In 1976, he founded St. Jude Medical, introducing the Björk-Shiley tilting-disc valve successor—the iconic St. Jude Medical mechanical heart valve. Constructed from pyrolytic carbon, this bihemispheric mechanical valve transformed heart valve replacement surgery, providing unmatched hemodynamic performance and durability. Decades later, the indelible impact of Villafaña’s creation culminated in Abbott’s acquisition of St. Jude Medical for $30 billion.
Expanding the Horizon: GV Medical, ATS, and Kips Bay Medical
Villafaña’s appetite for disruptive innovation remained unquenched. Over the subsequent decades, he founded:
- GV Medical: Pioneered advanced laser-enhanced angioplasty systems designed to clear arterial blockages with precision light energy.
- ATS Medical: Developed innovative surgical cryoablation and heart valve technologies, culminating in its acquisition by Medtronic for $400 million.
- Kips Bay Medical: Focused on engineering a specialized nitinol saphenous vein graft external support device intended to prevent the degradation of vein grafts during coronary artery bypass graft (CABG) surgery.
The Current Frontier: Medical 21 and the Maverics Graft
Never one to slow down, Villafaña’s latest venture is Medical 21, where he serves as founder and CEO. The company is currently developing the Maverics small-diameter artificial regenerative bypass graft for CABG surgery.
Traditional CABG procedures rely heavily on invasive vessel harvesting—surgically removing the patient’s own saphenous vein from the leg or the internal mammary artery from the chest wall. This harvesting process adds significant operative time, increases patient morbidity, causes chronic postoperative pain, and creates secondary surgical sites prone to infection.
The Maverics graft aims to render vessel harvesting obsolete. Fabricated from a bio-resorbable synthetic polymer scaffold reinforced with super-elastic nitinol wire, the Maverics graft is designed to serve as an off-the-shelf, small-diameter artificial conduit that mimics the compliance and patency of natural blood vessels while encouraging natural tissue regeneration. If successfully commercialized, this technology will represent a seismic shift in cardiac surgery, eliminating harvest-site morbidity and streamlining one of the most common surgical procedures in the world.
Supporting Context & Metrics: The Anatomy of Modern Minimally Invasive Medtech
The 2026 MDO Min-Vasive Medtech webinar series does not exist in a vacuum. It is part of a broader, sustained journalistic and industry focus on the structural shifts occurring across medical device design. Minimally invasive approaches have fundamentally rewritten the risk-benefit analysis for surgical interventions.
Historical Context of the MDO Series
The pedigree of the MDO Min-Vasive series is underscored by the caliber of past speakers who have graced the virtual stage:
- 2024 Event: Featured elite engineering and executive voices from Abbott, Johnson & Johnson MedTech’s DePuy Synthes, Synchron (pioneering endovascular brain-computer interfaces), and Endiatx (pioneering micro-robotic visualization pills).
- 2025 Event: Highlighted structural heart, catheter, and pediatric device development experts from Edwards Lifesciences, Jupiter Endosonics, and Compremium.
The Enabling Technologies
The ongoing success of minimally invasive therapies is propelled by advances in material science and engineering disciplines. Key technological pillars highlighted throughout the MDO coverage include:
- Nitinol (Nickel-Titanium Alloy): Celebrated for its unique shape memory and super-elastic properties, nitinol allows medical devices—such as stents, heart valve frames, and vascular grafts—to be compressed into ultra-thin catheters, navigated through tortuous tortuous anatomical pathways, and deployed to self-expand precisely within target lesions.
- Bioabsorbable Polymers: Materials engineered to provide mechanical integrity during the critical healing or tissue-remodeling phase before safely degrading and metabolizing into the body, eliminating long-term foreign body inflammatory responses.
- Next-Generation Catheters and Robotics: Enhanced torque transmission, steerable tip mechanisms, and robotic integration allow physicians to execute micro-level interventions with sub-millimeter precision, drastically reducing blood loss and recovery times.
Official Statements and Industry Insights
The curriculum for the upcoming webinar series has been meticulously designed to extract actionable insights from industry titans. During his keynote, Manny Villafaña will address some of the most complex, high-stakes questions facing modern medical device entrepreneurs and R&D executives:
- Navigating the Innovation Lifecycle: How to systematically move a concept from a napkin sketch through bench testing, preclinical validation, and first-in-human clinical trials.
- Mastering Regulatory Strategy: Insights on engaging regulatory bodies like the U.S. Food and Drug Administration (FDA) early and effectively to de-risk development pathways.
- Identifying True Unmet Clinical Needs: Avoiding the trap of "technology looking for a problem" and instead anchoring engineering efforts in deep clinical pain points experienced by physicians and patients.
- The Make-vs-Buy Dilemma: Strategic guidance on when a startup should build specialized engineering and manufacturing expertise in-house versus when to forge strategic alliances with external contract development and manufacturing organizations (CDMOs).
Jim Hammerand, managing editor of Medical Design & Outsourcing, emphasized the value of the upcoming sessions:
"Manny Villafaña has repeatedly done what many industry professionals consider impossible: he has built multi-billion-dollar companies from scratch by identifying major gaps in cardiovascular care and engineering elegant, durable solutions. Having him kick off our 2026 Min-Vasive Medtech series provides our audience—ranging from early-stage startup founders to seasoned tier-one OEM engineers—with an unprecedented masterclass in medtech leadership."
Future Outlook: What to Expect from the August 2026 Series
As healthcare systems grapple with aging global populations and an exponential rise in chronic cardiovascular and structural heart diseases, the demand for sophisticated, tissue-sparing interventions will only accelerate. The convergence of advanced biomaterials, artificial intelligence-assisted surgical planning, and micro-robotics points toward a future where highly invasive open surgeries are relegated to rare exceptions rather than the norm.
The 2026 MDO Min-Vasive Medtech Webinar Series (August 18–20, 2026) serves as a critical intellectual forum for engineers, product developers, regulatory affairs specialists, and executive leadership teams striving to shape this future.
How to Participate
- Dates: August 18–20, 2026.
- Time: 9:00 a.m. – 10:00 a.m. Pacific / 11:00 a.m. – 12:00 p.m. Central / 1:00 p.m. – 2:00 p.m. Eastern.
- Format: Three daily one-hour webinars featuring expert presentations followed by live, interactive Q&A sessions with the audience.
- Registration: Completely free and open now. Attendees can register once to secure access to all three sessions and seamlessly integrate calendar invites into their schedules.
With Manny Villafaña opening the series on Day 1, and two additional pioneering speakers to be announced shortly covering advanced medtech materials, components, and manufacturing ecosystems, the 2026 series promises to be an unmissable event for anyone dedicated to pushing the boundaries of modern medical device design.